Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 198
2 121.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd
Cost of Revenue
Caplin Point Laboratories Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
Cost of Revenue
-₹7.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-21%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹84.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹87.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹104.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹27.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cost of Revenue
-₹34B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Caplin Point Laboratories Ltd
Glance View
Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu. The firm is producing, developing and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals, and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. The Company’s principal research and development facilities are located in Tamil Nadu, India. Its principal manufacturing facility is located in Puducherry, India. The Company’s subsidiaries include Caplin Point Far East Limited, Caplin Point (S) PTE Ltd, Caplin Steriles Limited and Caplin Point Laboratories Colombia SAS.
See Also
What is Caplin Point Laboratories Ltd's Cost of Revenue?
Cost of Revenue
-7.6B
INR
Based on the financial report for Sep 30, 2024, Caplin Point Laboratories Ltd's Cost of Revenue amounts to -7.6B INR.
What is Caplin Point Laboratories Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-21%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for Caplin Point Laboratories Ltd have been -14% over the past three years , -17% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
